Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

about

Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.

P2860

Q38600392-AB4A1A30-E9F6-4553-ABAA-19E8C7CE8586

P2860

Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

Item

http://www.wikidata.org/entity/Q47574970

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@en

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@nl

type

Item

label

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@en

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@nl

prefLabel

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@en

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@nl

P1476

Dalteparin or vitamin K antago ...... alysis for France and Austria.

@en

P2093

Gunar Stemer

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Galanaud

http://www.w3.org/2001/XMLSchema#string

Lesley G Shane

http://www.w3.org/2001/XMLSchema#string

Seth Woodruff

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Review of the cost of venous thromboembolism

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Development of WHO guidelines on generalized cost-effectiveness analysis.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.

A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.

Assessing risk of venous thromboembolism in the patient with cancer.

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.

P2888

s00520-017-3610-2

P304

2093-2102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-017-3610-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Debourdeau

G Dranitsaris

P577

2017-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28204995

http://www.w3.org/2001/XMLSchema#string

P921

vitamin K

venous thromboembolism

Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

about

P2860

P2860

Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921